Möchten Sie immer auf dem neuesten Stand bleiben?

NUC-3373 Shows Encouraging Efficacy Signals and a Favorable Safety Profile in Patients with Advanced Colorectal Cancer NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer...

Presented Encouraging Clinical Data for NUC-3373 and NUC-7738 Continued to Enroll Global Phase III Biliary Tract Cancer Study (NuTide:121) of Acelarin with Potential for Accelerated Approval Filing ...

EDINBURGH, United Kingdom, Feb. 25, 2021 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...

Promising Efficacy Signals Including a 62% Disease Control Rate and a Partial Response in Patients who had Progressed on Prior Fluoropyrimidine Therapy Safety Profile Continues to be Favorable ...

Pharmaceutical Executive Brings a Wealth of Experience to NuCana’s Board of Directors Previously Served as CEO of Algeta, Chairman of Wilson Therapeutics and Chairman of KaNDy Therapeutics ...

Acelarin plus Cisplatin’s High Objective Response Rate and Favorable Safety Profile Confirmed NuTide:121 Global Phase III Study Recruitment Ongoing EDINBURGH, United Kingdom, Nov. 30, 2020 (GLOBE...

Completed Successful $80 million Public Offering Presented Encouraging Data for NUC-3373 and NUC-7738 at the ESMO Virtual Congress 2020 EDINBURGH, United Kingdom, Nov. 19, 2020 (GLOBE NEWSWIRE) --...

EDINBURGH, United Kingdom, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...

EDINBURGH, United Kingdom, Nov. 12, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...

EDINBURGH, United Kingdom, Oct. 13, 2020 (GLOBE NEWSWIRE) -- NuCana plc, a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer,...